Press Release

Paris, September 15th, 2019

PRESS RELEASE


TheraPanacea receives €2,5 million euros non-dilutive grant from European Union prestigious H2020 SME Instrument call program to develop the first AI-based fully Magnetic Resonance based Solution for Treatment planning in Radiation Therapy.


TheraPanacea, the France-based medtech company, with an expertise in medical imaging, mathematics and data sciences applied to oncology, receives 2,5 million euros non-dilutive grant from the EU Horizon 2020 EIC Accelerator (SME Instrument Phase 2 call).

The SME instrument program supports the most innovative European businesses with ground-breaking concepts that could shape new markets and disrupt existing ones in Europe and worldwide. A total of 1280 companies from 38 countries applied for this call, out of those 65 were approved for funding.

This funding will enable TheraPanacea to accelerate the development, clinical studies and commercialization of the first fully-adaptive and AI-powered treatment planning suite that can enable automated and non-toxic MR-guided radiotherapy in collaboration with leading Frenchand European cancer care centers such as Gustave Roussy (France), Institut de Cancérologie de Montpellier (France) and Tübingen Universität (Germany).

«TheraPanacea through this highly competitive award has a unique opportunity to reinvent cancer care by coupling the latest advances in artificial intelligence with the latest state-of-the-art MR-Linac technology. We are extremely honoured to receive this prestigious

recognition from the European Innovation Council that will help us to take radiation therapy to an unprecedent level of precision, clinical efficiency and clinical outcomes.» quotes Pr. Nikos Paragios, CEO of TheraPanacea.

Radiotherapy is one of the most widely-used treatment against cancer, with 60% of European cancer patients treated. However, current treatment planning software for radiotherapy heavily rely on toxic CT-imaging which leads to undesirable toxic radiation of patients with no option of plan adjustment during therapy and non-optimal clinical outcomes. Clinical studies of the project will be run with three European reference cancer centers, who fully supports the vision of a future radiotherapy that will fully leverage non-toxic MRI-imaging in radiotherapy.


// About TheraPanacea

TheraPanacea is a French based medtech founded in 2017, with a strong expertise in medical imaging, advanced mathematics and data sciences. It develops a new generation of intelligent software solutions for diagnosis, prognosis and treatment of cancer, starting with radio-oncology. Its first software product ART-Plan™ for adaptive radiotherapy is available on the European market since beginning of 2019.

// For more information : Catherine Martineau-Huynh, c.huynh@therapanacea.eu